Rankings / Metabolic Health

Orforglipron

Metabolic Health · Oral GLP-1 agonist (small molecule)

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

glp-1oralprescription
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Orforglipron as B (6.8/10) based on strong evidence, high benefit magnitude, and a med-risk safety profile.

ATTAIN-1 (n=3127, obesity, 72 wk): -11.

Studied, labeled, or reported-use context: Foundayo label: 0. — Rx; not individualized guidance.

What the evidence says

ATTAIN-1 (n=3127, obesity, 72 wk): -11.2% mean weight loss with >=10% loss in 54.6%. ATTAIN-2 (T2D + obesity): -10.5% at 36 mg. ACHIEVE-3 head-to-head vs oral semaglutide 14 mg: orforglipron 36 mg superior — A1c -2.2% vs -1.4%, weight -9.2% vs -5.3%. FDA approved Foundayo on April 1, 2026 as a once-daily oral GLP-1 pill for chronic weight management; label dosing uses lower tablet strengths up to 17.2 mg and adds GLP-1 class warnings plus CYP3A4/OATP1B interaction cautions. Convenience advantage over oral semaglutide is significant — no fasting, no water restrictions. ATTAIN-MAINTAIN (Phase 3b, Nature Medicine 2026): after reaching a weight plateau, orforglipron maintained ~75-79% of prior weight reduction vs ~38-49% on placebo at week 52. ACHIEVE-2 (Lancet 2026, n=962, T2D on metformin, 40 wk, head-to-head vs dapagliflozin 10mg): all three orforglipron doses (3/12/36mg) were non-inferior and statistically superior to dapagliflozin on HbA1c (-1.23% to -1.56% vs -0.81%, all p<0.0001), though with higher GI-related discontinuation (15-20% vs 6%).

Mechanism

Small-molecule (non-peptide) GLP-1 receptor agonist; ~79% oral bioavailability; no food/water restrictions (unlike oral semaglutide); biased agonism — stimulates cAMP without β-arrestin recruitment, potentially reducing receptor desensitization

Studied, labeled, or reported dose & route

Foundayo label: 0.8 mg once daily initially; 2.5 mg after >=30 days; then 5.5 mg with optional escalation to 9 mg, 14.5 mg, or 17.2 mg based on response/tolerability; no food/water restrictions

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Orforglipron's effects?
Read Off Label rates the evidence for Orforglipron as Strong and the benefit magnitude as high, producing an overall grade of B (6.8/10). ATTAIN-1 (n=3127, obesity, 72 wk): -11.
What safety findings are reported for Orforglipron?
Orforglipron has a med risk profile in the database. Med (GI effects common; label warnings for pancreatitis, severe GI reactions, AKI from volume depletion, hypoglycemia, gallbladder disease, aspiration risk) Legal status: Rx (FDA-approved April 1, 2026 as Foundayo for chronic weight management).
What doses or routes are reported for Orforglipron?
Foundayo label: 0.8 mg once daily initially; 2.5 mg after >=30 days; then 5.5 mg with optional escalation to 9 mg, 14.5 mg, or 17.2 mg based on response/tolerability; no food/water restrictions This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Orforglipron work?
Small-molecule (non-peptide) GLP-1 receptor agonist; ~79% oral bioavailability; no food/water restrictions (unlike oral semaglutide); biased agonism — stimulates cAMP without β-arrestin recruitment, potentially reducing receptor desensitization

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.